TELA Bio, Inc. TELA
Medical/Dental Instruments · IPO 2019 · data as of November 13, 2026
TELA Bio, Inc. (TELA) is a healthcare company listed in the US with a market value of about $37M. In the twelve months to September 30, 2026 it had revenue of $78M and net income of -$42M, a net margin of -53.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 35% a year, a 5-year average ROIC of -49%.
About TELA Bio
TELA Bio is listed in the US and classified in medical/dental instruments, IPO year 2019. Revenue went from $4M in 2017 to $80M in 2025, growth of about 44.4% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 189% over three years (dilution for shareholders). It spends 11% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78M | $80M | $69M | $58M | $41M | $29M | $18M | $15M | $8M | $4M |
| Net income | -$42M | -$39M | -$38M | -$47M | -$44M | -$33M | -$29M | -$22M | -$21M | -$21M |
| Free cash flow | -$34M | -$29M | -$43M | -$41M | -$42M | -$31M | -$25M | -$26M | -$20M | -$16M |
| EPS (diluted) | $-0.74 | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 | $-17.10 | $-101.41 | $-73.07 |
| Net margin | -53.6% | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% | -145.2% | -254.9% | -502.6% |
| ROIC | — | -41.7% | -47.5% | -56.5% | -55.2% | -45.1% | -25.0% | -24.7% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does TELA Bio pay a dividend?
Not currently.
Is TELA Bio a good stock to buy?
We do not give buy or sell advice. TELA Bio scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.